Shingrix shot after bone marrow transplant to prevent shingles
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 2 study tests whether an additional Shingrix (RZV) vaccine dose helps prevent shingles in people who previously had an allogeneic bone marrow or stem cell transplant. It focuses on people who are at least a year out from their first two Shingrix doses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had an allogeneic bone marrow or stem cell transplant when you were age 18–79
- You received two Shingrix doses between 2 and 6 months apart, and at least 1 year after your transplant
- You are at least 18 months after your second Shingrix dose to enroll
- If you can become pregnant: use effective birth control for the required timeframe, and have a negative pregnancy test on vaccine days
- You must be able and willing to follow the study schedule and visit plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether the shingles vaccine Shingrix is safe and effective for adults with chronic kidney failure who are on the transplant waiting list. It aims to protect you from shingles while you may be dealing with transplant-related immune changes.
This study tests whether an extra dose of the Shingrix shingles vaccine can boost protection in people who have had a solid-organ transplant. If you already received both doses of Shingrix after your transplant, this trial will give you an additional dose to see if it further strengthens your immune response.
This Phase 2 study looks at how well the shingles vaccine works in people who had an allogeneic (donor) stem cell transplant. It aims to measure the body’s immune response to the vaccine and check that it’s safe in this recovery period.
This trial tests whether the shingles vaccine (RZV) is safe and works well for organ transplant recipients and their household members. It also includes people on dialysis or certain immunosuppressants.
This study tests the shingles vaccine in young adults who have had a solid organ transplant (like a kidney or liver) more than a year ago. The goal is to see if the vaccine works well and is safe for people on stable anti-rejection medicines.
This trial tests whether Shingrix (a shingles vaccine) is safe and works well in adults with rheumatic or immune-related conditions. It compares Shingrix to a placebo (inactive shot) to see how well it prevents shingles and affects immune symptoms.
Hear when a new Bone Marrow Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.